Medtronic has announced a strategic partnership with Cornerstone Robotics, committing approximately $700 million to expand its robotic-assisted surgery portfolio globally.

The investment secures distribution rights for Cornerstone's Sentire surgical system in select markets outside the United States where regulatory approval is obtained. This move allows Medtronic to offer a diversified range of surgical solutions alongside its existing Hugo robotic-assisted surgery (RAS) system.

Strategic Portfolio Expansion

Medtronic will distribute Sentire in tandem with Hugo, creating a unique multi-port portfolio of robotic solutions. The two platforms are designed to be complementary, providing surgeons and health systems with greater choice and flexibility tailored to diverse clinical settings and procedural needs.

The partnership aims to address the current limitation in global adoption of robotic-assisted surgery, which remains in the single digits. By expanding access through multiple platforms, Medtronic seeks to reach more patients worldwide while offering health systems varied economic models and clinical options.

Key Deal Terms

What the Numbers Show

The $700 million commitment represents a significant capital allocation toward market expansion rather than immediate revenue generation. By acquiring distribution rights rather than full ownership, Medtronic leverages this investment to diversify its product offering against the backdrop of low global adoption rates for robotic surgery. This strategy positions the company to capture a larger share of the growing minimally invasive surgery market by addressing varied economic and clinical requirements across international health systems.

Medtronic plc (NYSE: MDT) raised its fiscal 2027 adjusted earnings per share guidance to a range of $5.94 to $6.00. This update places the midpoint of the company’s outlook just above the $5.95 analyst estimate, reflecting confidence in sustained operational momentum.

The medical technology leader reported first quarter fiscal 2027 revenue of $9.8 billion, an increase of 13.7% on both an as-reported and organic basis. The results, for the period ended July 31, 2026, reflect strong execution in cardiovascular and medical surgical segments. An extra fiscal week in the first quarter contributed approximately $570 million to organic growth, while favorable foreign exchange added $57 million to reported sales.

Financial Performance

Medtronic’s GAAP operating profit reached $1.76 billion, up 22.1% year-over-year, with operating margins expanding 120 basis points to 18.1%. On a non-GAAP basis, operating profit was $2.32 billion, representing a 14.9% increase and a stable operating margin of 23.7%.

GAAP net income attributable to Medtronic rose 41.4% to $1.47 billion, driven by higher operating profits and non-operating income. Non-GAAP diluted earnings per share (EPS) came in at $1.45, exceeding the company’s previous guidance range.

Portfolio Growth Drivers

The cardiovascular portfolio led the charge with organic revenue growth of 18.9%, reaching $3.93 billion. This performance was anchored by high-20s growth in Electrophysiology Therapies and double-digit gains in Interventional Cardiology and Peripheral Vascular Health.

Neuroscience revenue grew 9.3% organically to $2.68 billion, supported by low-double-digit increases in Cranial and Spinal Technologies. The Medical Surgical portfolio also performed strongly, posting 10.2% organic growth to $2.28 billion, led by mid-teens growth in Acute Care and Monitoring.

Guidance and Strategic Moves

Management raised its fiscal 2027 organic revenue growth guidance by 50 basis points to a range of 7.25% to 7.75%, up from the prior estimate of 6.75% to 7.25%. Concurrently, the full-year non-GAAP diluted EPS guidance was increased to $5.94 to $6.00 from $5.90 to $6.00. This revised guidance stands against an analyst estimate of $5.95.

Strategically, Medtronic announced expanded CE Mark indications for its Affera Mapping and Ablation System and completed acquisitions of Scientia Vascular and SPR Therapeutics. The company also secured a strategic partnership with Cornerstone Robotics to expand access to robotic-assisted surgery.

What the Numbers Show

A significant divergence exists between GAAP and non-GAAP profitability metrics due to substantial non-cash charges. While GAAP operating margins expanded by 120 basis points to 18.1%, non-GAAP margins remained flat at 23.7%. This indicates that the top-line revenue growth of 13.7% translated directly into operational efficiency, but GAAP results were weighed down by $412 million in amortization of intangible assets and $72 million in restructuring charges, which are excluded from the non-GAAP view.

Free cash flow surged to $1.29 billion, more than doubling the $584 million recorded in the prior-year period, highlighting improved cash conversion despite heavy investment in acquisitions totaling $1.16 billion.